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Background: Knowledge about COVID-19 infections is expanding, although knowledge about the disease course
and antibody formation in patients with an auto-immune disease or immunodeficiency is not fully unraveled yet.
It could be hypothesized that immunodeficient patients, due to immunosuppressive drugs or their disease, have a
more severe disease course due to their immunocompromised state. However, it could also be hypothesized that
some of the immunosuppressive drugs protect against a hyperinflammatory state.
Methods: We collected data on the incidence of COVID-19, disease course and SARS-CoV-2 antibody formation in
COVID-19 positive patients in a cohort of patients (n ¼ 4497) known at the Clinical Immunology outpatient clinic
in a tertiary care hospital in the Netherlands.
Results: In the first six months of the pandemic, 16 patients were identified with COVID-19, 14 by nasal swab PCR,
and 2 patients by SARS-CoV-2 antibodies. Eight patients were admitted to the hospital. SARS-CoV-2 antibodies
were measured in 8 patients and were detectable in all, including one patient on B-cell ablative therapy and one
patient with Common Variable Immunodeficiency Disorder.
Conclusion: This study indicates that the disease course differs among immunocompromised patients, indepen-
dently of (dis)continuation of immunosuppressive drugs. Antibody production for SARS-CoV-2 in immunocom-
promised patients was shown. More research needs to be conducted to confirm these observations and guidelines
regarding (dis)continuation of immunosuppressive drugs in COVID-19 positive immunocompromised patients
should be developed.1. Introduction
An infection with SARS-CoV-2 causes symptoms of the respiratory
tract, but increasing evidence shows that almost every organ system can
be involved [1,2]. In some patients, the disease course can be compli-
cated by a potentially fatal cytokine-driven hyperinflammatory response
[3–5]. It may be suggested that immunocompromised patients, either
due to a primary immunodeficiency or a secondary immunodeficiency
caused by the usage of immunosuppressive drugs, are at increased risk
for infection and a more severe disease course with SARS-CoV-2 [6].
Conclusive data on this subject are missing, however. On the other hand,
specific immunosuppressive drugs are used in the treatment of the
hyperinflammatory state [7–9]. It could therefore be hypothesized that
anti-cytokine therapy could mask the symptoms of an infection with0, 3015, GD, Rotterdam, the Ne
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vier B.V. This is an open access aCOVID-19 or alter the disease course. Furthermore, there are not much
data on the antibody production of SARS-CoV-2 in immunocompromised
patients. To delineate the effect of an underlying immunological condi-
tion and/or immunosuppression on the course of COVID-19, we per-
formed a descriptive study to investigate the incidence, disease course
and SARS-CoV-2 antibody production in a cohort of patients with a pri-
mary or secondary immunodeficiency. For this study, approval from the
medical ethical committee was requested and obtained.
2. Results and discussion
Our cohort consists of 4497 patients that are attending the outpatient
clinic of the department of Clinical Immunology at the Erasmus Uni-
versity Medical Center (Rotterdam, the Netherlands). From the start oftherlands.
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the patients known at the Clinical Immunology clinic referred to the
emergency department and/or being admitted at the ward or ICU
because of (a suspicion of) COVID-19 were collected prospectively. In
addition, all patients at the immunology outpatient clinic, with auto-
immune, auto-inflammatory and primary immunodeficiency diseases,
are instructed to contact the Clinical Immunology department when they
have symptoms of an infection. From the start of the COVID-19 epidemic
in the Netherlands patients were questioned about potential COVID-19
symptoms in the outpatient clinic, and when admitted elsewhere corre-
spondences from other hospitals were collected. Data on clinical features
and use of immunosuppressive drugs in patients with COVID-19 known
at the Clinical Immunology department were analyzed in the first six
months of the epidemic until August 2020. Furthermore, the incidence of
COVID-19 in our cohort was investigated. A total of 67 patients in our
cohort were tested for SARS-CoV-2 by nasopharyngeal swab, of whom 14
tested positive for COVID-19 infection (21%) (Table 1). Two patients
(patient 10 and 13) had typical COVID-19 symptoms, but did not have a
PCR-test at the time of symptoms. Afterwards these patients demon-
strated serum SARS-CoV-2 antibodies.
The clinical symptoms differed significantly among patients. Some
patients only presented with fever, or minor symptoms, whereas other
patients presented with severe respiratory symptoms. Half of the patients
(8/16) were admitted to the hospital and 3 of them were admitted to the
Intensive Care Unit (ICU). A mortality rate of 2/16 was reported. Both
deaths concerned patients of 85 years and above. One patient used
dexamethasone for chronic spontaneous urticaria and the other immu-
noglobulin substitution therapy for a secondary immunodeficiency due
to COPD. The incidence of SARS-CoV-2 by nasal swab PCR in this cohort
is 14/4497¼ 0.31% in the first six months, compared to the incidence of
67543/17 445 447 ¼ 0.39% in the first six months in the generalTable 1
Clinical features of the COVID-19 positive patients.
Patient, age/
gender
Admission Diagnosis IgM Ig Duration
(D)
1, 40/F Home CVID 1 1 41 days
2, 21/F GW, 9 days BD 1 1 18 days
3, 46/F GW, 19 days
ICU, 29 days
MV
NMO 1 1 56 days
4, 63/F GW, 17 days Sarcoidosis 1 1 60 days
5, 64/F NH SADNI x x 16 days
6, 50/F GW, 7 days ASS 1 x 74 days
7, 91/M NH, dec. Chronic
urticaria
x x Unknown
8, 85/M GW, 7 days, dec. Secondary IMD x x 10 days
9, 33/F Home Polymyositis 1 1 50 days
10, 51/F Home SS with PH 1 1 31 days
11, 54/M ICU, 21, days, no
MV
BD, NPC x x 21 days
12, 49/F ICU, 6 days, MV BD x x 25 days
13, 54/F Home Sarcoidosis 1 1 Unknown
14, 34/F Home BD x x 14 days
15, 57/M GW, 8 days RP x x 8 days
16, 28/M Home BD x x 19 days
ASS ¼ Anti-synthetase syndrome, BD ¼ Behçet’s disease, BMI ¼ Body Mass Index
Disorder, D¼ the duration of illness defined as the amount of days between the first da
¼ female, GW ¼ general ward, HCQ ¼ hydroxychloroquine, IC ¼ Intensive Care, IF
munodeficiency, ISD ¼ immunosuppressive drugs, LOTS ¼ loss of sense of taste and sm
associated neuromyelitis optica, NPC ¼ Nasopharyngeal carcinoma, MV ¼ mechani
SADNI ¼ Selective Antibody Deficiency with Normal Immunoglobulins, SS ¼ system
a ¼ discontinued upon positive COVID-19 test.
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population of the Netherlands in that period [10,11].
Antibodies weremeasured in 8 patients in total, in 6 patients who also
had a positive PCR-SARS-CoV-2 test. In a subgroup of patients antibodies
were not measured because patients had not attended the out-patient
clinic yet. In 5/6 PCR-positive patients, both the isotypes IgM and total
Ig were detectable. One patient, with a very recent infection, only
showed positive IgM antibodies. Of those 6 SARS-CoV-2 positive pa-
tients, 5 patients used immunosuppressive drugs at the time of infection
with COVID-19. Immunosuppressive drugs were discontinued in 4 of
them during the disease course (Table 1). Patient 9 was treated with
rituximab (B-cell ablative therapy) three months before infection because
of polymyositis. Rituximab targets the CD20 antigen and the effect lasts
for approximately 3–8 months [12]. Remarkably, both IgM and total Ig
antibodies, measured four weeks after the first signs of COVID-19, were
positive. By using FACS analysis no B-cells could be detected in periph-
eral blood of this patient, although plasmablasts were still detectable in
peripheral blood. No admission to the hospital was needed and she
recovered well at home. This case unexpectedly illustrates that patients
using immunosuppressive drugs, even immunosuppressive drugs tar-
geting the B-cells, still can produce antibodies against SARS-CoV-2.
COVID-19 antibodies were also seen in our cohort in patients with non-B
cell ablative immunosuppressive drugs.
A total of 2 patients were diagnosed with a primary immunodefi-
ciency. Patient 1 was known with Common Variable Immunodeficiency
Disorder (CVID), an primary immunodeficiency characterized by an
increased risk of infections and deficit of antibody production due to an
impaired B-cell differentiation [13]. She was diagnosed with CVID 1 year
ago and had not yet started with immunoglobulin substitution. She
presented with mild respiratory symptoms and fever. The PCR-test for
SARS-CoV-2 was positive and she fully recovered at home. She was
described in an international study [14], where she had a less severeBMI (kg/
m2)
Symptoms ISD
24.2 Cough, ST, fever, dyspnea,
chest pain, sinusitis
–
27 CC, cough, fever, dyspnea,
diarrhea
Colchicine, prednisone, IFXa, dapsone
34 CC, fever, dyspnea Mycophenolic acida
Rituximab (10 months earlier)








22.4 Cough, fever, dyspnea IgG suppletion





29.1 Pneumonia Colchicine, Azathioprine,
chemotherapy
31.9 Dyspnea, headache, cough Colchicinea





21 CC, ST, headache Apremilast
(in kg/m2), CC ¼ common cold, CVID ¼ Common Variable Immunodeficiency
y of reported symptoms and the last day of reported symptoms, dec.¼ deceased, F
X ¼ infliximab, Ig ¼ total Ig-SARS-CoV-2, IgM ¼ IgM-SARS-CoV-2, IMD ¼ im-
ell, M ¼male, MTX ¼methotrexate, NH ¼ Nursing Home, NMO ¼ aguaporine-4
cal ventilation, PH ¼ pulmonary hypertension, RP ¼ Relapsing polychondritis,
ic sclerosis, ST ¼ sore throat, x ¼ not tested, 1¼positive.
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then. Both IgM-SARS-CoV-2 and total Ig-SARS-CoV-2, measured seven
weeks after the first symptoms, were positive despite an impaired B-cell
function. Patient 5 was known with Selective Antibody Deficiency with
Normal Immunoglobulins (SADNI). She was already being treated with
immunoglobulins and presented with fever as the only symptom and
recovered well without other treatments.
In this observational cohort we studied the characteristics and anti-
body formation in COVID-19 positive patients and the incidence of
COVID-19 in patients known at the immunology department in the first
six months of the pandemic. Out of the total cohort of 4479 outpatients,
known at the outpatient clinic, sixty-seven patients were tested for
COVID-19 by nasal swab PCR, of which fourteen (21%) had COVID-19.
Initially, test capacity in the Netherlands was limited and was only
restricted to patients withmore severe symptoms who were attending the
hospital. At a later stage, only patients that showed clinical symptoms of
an infection were allowed to be tested. As a consequence, patients who
were asymptomatic or who did not report symptoms might have been
missed. The reported incidence could therefore be an underestimation.
Moreover, the cohort was not screened systemically, which could also
cause underestimation of the incidence and a overestimation of the
percentage of admission. However, this study suggests that the incidence
of a COVID-19 infection in immunocompromised patients does not seem
to be increased compared to the general population. This was also re-
ported by others at the beginning of the pandemic [15]. Whether this is a
result of strict adherence to quarantine measures, or due to an underes-
timation because not all patients might have reported their COVID-19
symptoms, cannot be answered by this study. A larger systematical
study should be conducted to determine the incidence more accurately in
this patient population. A relatively large proportion of the COVID-19
positive patients had to be admitted to the hospital (50%), both pa-
tients who continued the immunosuppressive drugs as well as patients
who discontinued these drugs. The proportion of admissions in the
general population was 18% [11]. Furthermore, 3/16 (19%) patients
were admitted to the ICU. This would suggest that the disease course is
more protracted in immunocompromised patients, however the number
of COVID-19 infections is too small to draw any definitive conclusions. In
addition, if the incidence of COVID-19 is actually higher because of un-
derestimation of the number of mild cases staying at home, the propor-
tion of patients being admitted would be lower. Previously, it has been
reported that the admission rate in patients with rheumatic diseases was
44% and was similar to those without rheumatic diseases, but patients
with a rheumatic disease did require ICU and mechanical ventilation
more often [16]. In the present study the number of ICU admissions was
not as high as reported previously, but seems higher than in the general
population [16]. In a few patients the duration of disease was quite long.
This is however fully based on whether patients still reported symptoms
of COVID-19, even minor. This is also reflected by the duration patients
were admitted, which is much shorter than the duration of reported
symptoms in most of them. Whether the disease duration is prolonged in
immunocompromised patients deserves further study.
At the moment, there is no universal guideline about the continuation
of immunosuppressive drugs during a COVID-19 infection [17]. This
decision should be made for each patient individually. The number of
patients in this study was too small to determine the exact effect of
immunosuppressive drugs on the disease course. A meta-analysis showed
a more protracted course of a COVID-19 infection in patients using dis-
ease modifying antirheumatic drugs (DMARDs) or DMARD combination
therapy with a biological or targeted DMARD therapy, while biological
monotherapy, including anti-TNF monotherapy reduced the risk of a
severe COVID-19 infection [18]. Further studies are needed to confirm
this effect of immunosuppressive drugs in a COVID-19 infection.
An unexpected finding is the production of SARS-CoV-2 antibodies in
patients with either primary B-cell dysfunction or due to B-cell ablative3
therapy. The protection against a new infection and the half-time of these
antibodies is not yet investigated, and repeated antibodymeasurement in
time can provide more insight in to this.
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